All News

light-bulbs-1125016_640.jpg

A new score to quantify GCA inflammation?

Eric Dein, MD

The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. This approach is not well individualized to the patient as we do not account for the degree of inflammation that may or may not be present in the disease. Improved markers to stratify the extent of inflammation can help to tailor a more personalized approach to treatment.

Read Article
acr_session2.jpeg

ACR 2024 - Day 3 Report

Jack Cush, MD

Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.

Read Article
Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs

Links:

Richard Conway RichardPAConway ( View Tweet)
In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe

Links:

Jiha Lee JihaRheum ( View Tweet)
Difficult to Manage Axial Spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24 https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

In order to have a #DMOAD in knee #osteoarthritis ➡️ early detection may be v important Study of early pt Symptoms was done 2/3 had pain 1/2 #joint Swelling Need biomarkers & sensitive imaging in early #OA as symptoms are NOT uniform #ACR24 @RheumNow @ACRheum abst2111 https://t.co/K94m9rOjtP

Links:

Janet Pope Janetbirdope ( View Tweet)
Does #hand #osteoarthritis Benefit from #traction #splinting? Nope 👎 Small 2 site #RCT - not helpful I may Recommend #splinting - sometimes pts get Pain relief - in my opinion but this one didn’t help #ACR24 @RheumNow @ACRheum Abst#2108 https://t.co/K0Ud7uCb1P

Links:

Janet Pope Janetbirdope ( View Tweet)
Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops? Check out my article: Taking the AI out of AutoImmunity https://t.co/d3ZNYWQaaQ @RheumNow #ACR24

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

Conversation with @RheumKay on his #ACR24 biosimilar talk for @RheumNow https://t.co/LzAIGIG4wu https://t.co/CqSYLpJYAh

Links:

Eric Dein ericdeinmd ( View Tweet)

Lot said about #ACR24 ABST1697: MTX in newly diagnosed PMR, neg RCT Many have said no hope for MTX in PMR now Agree doesn't bode well However, MTX may still have role in established PMR @drceowen & I have made that call a priori @TheLancetRheum https://t.co/ywCJc0zHzC @RheumNow https://t.co/JUXk2tDNyR

Links:

David Liew drdavidliew ( View Tweet)
#Artificial #Intelligence can detect #osteoporosis On #CXR To detect #thoracic #vertebral #fractures > 100000 #chest #radiographs - test and validation cohorts found + results on ROC Helpful -sometimes vertebral changes are Not read on CXRs #ACR24 @RheumNow @ACRheum #2116 https://t.co/NxEaH0AKJv

Links:

Janet Pope Janetbirdope ( View Tweet)
#Publication #bias to Nth degree. >1/3 of registered #postmeno #osteoporosis trials are NOT #published 👇search of trials 673 published Vs 489 not published 890000 pts MOSTLY when performed in the USA No accountability for NOT publishing #ACRbest #ACR24 @RheumNow #2122 https://t.co/UyMMbHhvvV

Links:

Janet Pope Janetbirdope ( View Tweet)
It is NO LONGER a ACCEPTABLE To NOT consider #MMF or #Cyclo + another proven #Rx Added to #HCQ and #tapering /limiting #glucocorticoids RCTs in #lupus #nephritis support this ? Is which to add #belimumab #CNI #volclosporin #obinutuzimab #ACR #ACRbest @RheumNow @ACRheum https://t.co/a7WMFfCyXl

Links:

Janet Pope Janetbirdope ( View Tweet)

RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw

Dr. John Cush RheumNow ( View Tweet)

@DrLisaCS distills the challenges of MCTD 👇 🔵Clinical phenotyping key to improve patient outcomes @jhrheumatology @RheumNow #acr24 https://t.co/APfXPwxvfE

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow Day 3 Recap: ACR Convergence 2024 Highlights https://t.co/jFIATPKlp7

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×